13.50EUR0.00%Mkt Cap: 305.30M $P/E: —1d ago
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago …
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap305.30M $
Enterprise Value303.79M $
Revenue (TTM)20.79M $
Gross Profit20.79M $
Net Income (TTM)-14.39M $
Revenue/Share1.041 USD
Last Price13.50 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees27
CountryDE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-59.77
EV/Revenue14.61
P/S14.69
P/B-24.28
EPS (TTM)-0.66
EPS (Forward)—
52W Range
13.1530% of range14.30
52W High14.30 EUR
52W Low13.15 EUR
Profitability
Gross Margin100.00%
Oper. Margin-83.59%
EBITDA Margin-24.45%
Profit Margin-69.22%
ROE118.90%
ROA-33.05%
Growth
Revenue Growth-84.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF35.16M $
CapEx (TTM)52.17K $
FCF Margin205.61%
FCF Yield14.00%
Net Debt10.09M $
Net Debt/EBITDA-1.99
Balance Sheet
Debt/Equity-3.43
Current Ratio0.76
Quick Ratio0.70
Book Value/Sh-0.5560 EUR
Cash/Share1.443 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.20.81M
Float17.99M
Insiders13.11%
Institutions10.68%
Technical
SMA 5013.16 (+2.6%)
SMA 20018.05 (-25.2%)
Beta0.73
S&P 52W Chg18.16%
Avg Vol (30d)4.81K
Avg Vol (10d)5.38K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—